ERBB4

Salubris Biotherapeutics Presents Positive 6-Month Data from Phase 1b Clinical Trial of JK07 in Late-Breaking Session at The Heart Failure Society of America Annual Meeting 2023

Retrieved on: 
Monday, October 9, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Therapy, LVEF, EF, Heart failure, Disease, Quality of life, Protalix BioTherapeutics, Mortality, Heart, Heart failure with preserved ejection fraction, ERBB4, Patient, Pharmaceutical industry

Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced positive updated results from the completed Phase 1b study of JK07 in patients with HFrEF.

Key Points: 
  • Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced positive updated results from the completed Phase 1b study of JK07 in patients with HFrEF.
  • The data were presented in a late breaking oral session during the Heart Failure Society of America Annual Scientific Meeting 2023.
  • JK07 is the first investigational antibody fusion protein and first selective ErbB4 agonist to enter clinical development for heart failure.
  • Heart failure is a leading cause of morbidity and mortality globally, with estimates of more than 6 million patients affected by HFrEF and HFpEF in the US.

Salubris Biotherapeutics Presents Positive Updates from Phase 1b Clinical Trial of JK07 in Late-Breaking Session at the European Society of Cardiology Heart Failure 2023 Congress

Retrieved on: 
Saturday, May 20, 2023
Health, General Health, Clinical Trials, Research, Science, Cardiology, Biotechnology, Heart failure, Protalix BioTherapeutics, Cleveland Clinic, Therapy, ERBB4, LVEF, EF, Death, Patient, Heart, European Society of Cardiology, Cleveland, Pharmaceutical industry

Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced positive updated results from the ongoing Phase 1b study of JK07 in heart failure with reduced ejection fraction (HFrEF).

Key Points: 
  • Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced positive updated results from the ongoing Phase 1b study of JK07 in heart failure with reduced ejection fraction (HFrEF).
  • The data were presented in a late breaking oral session during the annual congress of the European Society of Cardiology’s Heart Failure Association.
  • JK07 is the first investigational antibody fusion protein and first selective ErbB4 agonist to enter clinical development for heart failure.
  • Heart failure is a serious health condition that contributes to one in eight deaths in the U.S. and impacts nearly 6.5 million Americans1.

Edison Oncology and Apollomics Announce Treatment of First Patient with EO1001 (APL-122) in a Phase I/IIa Clinical Trial

Retrieved on: 
Friday, October 1, 2021
Mortality, CNS, Glioblastoma, Clinical trial, Cancer, ErbB, GBM, Hope, Epidermal growth factor receptor, HER2/neu, HER2, Patient, ERBB4, Brain, III, T790M, Population, Central nervous system, Disease, Immune system, Lung cancer, Phase, NSCLC, CA, Principal, HER4, Company, Large-cell lung carcinoma, Entrepreneurship, MBA, TKI, Survival, Safety, Incidence, EGFR, Quality of life, Doctor of Philosophy, Breast cancer, Pharmaceutical industry, Medical imaging

"Our preclinical studies have shown that EO1001 is potent against multiple activating mutations in the intracellular domain of EGFR.

Key Points: 
  • "Our preclinical studies have shown that EO1001 is potent against multiple activating mutations in the intracellular domain of EGFR.
  • The Phase I/IIa clinical trial will enroll up to 50 patients and is being conducted in Australia under contract service provided by Senz Oncology Pty Ltd.
  • The objective of this first-in-human clinical trial is to examine the safety and tolerability of EO1001 in patients with metastatic or advanced stage ErbB-1(EGFR), ErbB-2(HER2) and/or ERbB-4 (HER4) positive cancer.
  • On February 9, 2021, Edison Oncology and Apollomics announced an exclusive licensing agreement whereby Apollomics will develop and commercialize EO1001 (APL-122) globally, except in Mainland China, Hong Kong and Taiwan.

Edison Oncology and Apollomics Inc. Announce Treatment of First Patient For EO1001 (APL-122) in a Phase I/IIa Clinical Trial

Retrieved on: 
Thursday, September 30, 2021
Mortality, CNS, Glioblastoma, Clinical trial, Cancer, ErbB, Hope, Epidermal growth factor receptor, HER2/neu, HER2, Patient, ERBB4, Brain, III, T790M, Population, Central nervous system, Disease, Lung cancer, Phase, NSCLC, Principal, HER4, GBM, Large-cell lung carcinoma, Entrepreneurship, MBA, TKI, Survival, Safety, Incidence, EGFR, Quality of life, Doctor of Philosophy, Breast cancer, GLOBE, Pharmaceutical industry, Medical imaging

Our preclinical studies have shown that EO1001 is potent against multiple activating mutations in the intracellular domain of EGFR.

Key Points: 
  • Our preclinical studies have shown that EO1001 is potent against multiple activating mutations in the intracellular domain of EGFR.
  • The Phase I/IIa clinical trial will enroll up to 50 patients and is being conducted in Australia under contract service provided by Senz Oncology Pty Ltd.
  • The objective of this first-in-human clinical trial is to examine the safety and tolerability of EO1001 in patients with metastatic or advanced stage ErbB-1(EGFR), ErbB-2(HER2) and/or ERbB-4 (HER4) positive cancer.
  • On February 9, 2021, Edison Oncology and Apollomics announced an exclusive licensing agreement whereby Apollomics will develop and commercialize EO1001 (APL-122) globally, except in Mainland China, Hong Kong and Taiwan.

Apollomics, Inc. and Edison Oncology Announce Licensing Agreement for Novel Protein Tyrosine Kinase Inhibitor Targeting Solid Tumors

Retrieved on: 
Wednesday, February 10, 2021
Tyrosine kinase receptors, Oncogenes, Branches of biology, Cancer, ErbB, Epidermal growth factor receptor, HER2/neu, Protein kinase inhibitor, Tyrosine kinase, ERBB4, Spectrum Pharmaceuticals, AEE788

EO1001 is a protein tyrosine kinase inhibitor (TKI) that has demonstrated irreversible inhibition of EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) as a single agent.

Key Points: 
  • EO1001 is a protein tyrosine kinase inhibitor (TKI) that has demonstrated irreversible inhibition of EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) as a single agent.
  • Under the terms of the agreement, Apollomics has the exclusive rights to develop and commercialize EO1001 globally, except in China, Hong Kong and Taiwan.
  • EO1001 is a protein tyrosine kinase inhibitor (TKI) that has demonstrated irreversible inhibition of EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) as a single agent.
  • Edison Oncology was founded in 2018 by experienced life science industry veterans to develop and commercialize new therapies targeting the fight against cancer.

Apollomics, Inc. and Edison Oncology Announce Licensing Agreement for Novel Protein Tyrosine Kinase Inhibitor Targeting Solid Tumors

Tyrosine kinase receptors, Oncogenes, Branches of biology, Cancer, ErbB, Epidermal growth factor receptor, HER2/neu, Protein kinase inhibitor, Tyrosine kinase, ERBB4, Spectrum Pharmaceuticals, AEE788

EO1001 is a protein tyrosine kinase inhibitor (TKI) that has demonstrated irreversible inhibition of EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) as a single agent.

Key Points: 
  • EO1001 is a protein tyrosine kinase inhibitor (TKI) that has demonstrated irreversible inhibition of EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) as a single agent.
  • Under the terms of the agreement, Apollomics has the exclusive rights to develop and commercialize EO1001 globally, except in China, Hong Kong and Taiwan.
  • EO1001 is a protein tyrosine kinase inhibitor (TKI) that has demonstrated irreversible inhibition of EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) as a single agent.
  • Edison Oncology was founded in 2018 by experienced life science industry veterans to develop and commercialize new therapies targeting the fight against cancer.

Human Epidermal Growth Factor Receptor 4 (HER-4 or ErbB-4) Inhibitor - Global Pipeline Insight Report 2019 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 6, 2019
Biotechnology, Pharmaceutical, Health, Tyrosine kinase receptors, Branches of biology, Oncogenes, Cell biology, Epidermal growth factor receptor, ErbB, ERBB4, ERBB3, Receptor tyrosine kinase

The "Human Epidermal Growth Factor Receptor 4 (HER-4 or ErbB-4) Inhibitor - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Human Epidermal Growth Factor Receptor 4 (HER-4 or ErbB-4) Inhibitor - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Human Epidermal Growth Factor Receptor 4 (HER-4 or ErbB-4) Inhibitor development.
  • The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
  • The report assesses the active Human Epidermal Growth Factor Receptor 4 (HER-4 or ErbB-4) Inhibitor pipeline products by developmental stage, product type, molecule type, and administration route.